|Adverse reactions usually occur in the first eight weeks of treatment. The most frequently occurring reactions are nausea, headache, arthralgia, mild gastric distress, skin rashes and pruritus. These reactions are usually self-limiting and may not require withdrawal of the drug.|
Blood and lymphatic system disorders
Bone marrow depression including neutropenia, eosinophilia and agranulocytosis have been reported. Fatalities with carbimazole induced agranulocytosis have been reported. Rare cases of purpura, anaemia, pancytopenia/aplastic anaemia, neutropenia, leucopenia and isolated thrombocytopenia have also been reported. Additionally, very rare cases of haemolytic anaemia have been reported.Patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, malaise and should be instructed to stop the drug and to seek medical advice immediately. In such patients, blood cell counts should be performed, particularly where there is any clinical evidence of infection.
Nervous system disorders
Gastro-intestinal system disorders
Nausea, mild gastric distress, loss of sense of taste has been observed.
General disorders and administration site conditionsFever, malaise.
Hepato-biliary system disorders
Hepatic disorders including abnormal liver function tests, hepatitis, cholestatic hepatitis, cholestatic jaundice and most commonly jaundice, have been reported; in these cases carbimazole should be withdrawn.
Injury, poisoning and procedural complicationsBruising.
Skin and subcutaneous tissue disorders
Skin rashes, pruritus, urticaria. Hair loss has been occasionally reported.
Musculoskeletal system disorders
Isolated cases of myopathy have been reported. Patients experiencing myalgia after the intake of NeoMercazole should have their creatine phosphokinase levels monitored.
Hypersensitivity and allergic reaction
Angioedema and multi-system hypersensitivity reactions such as cutaneous vasculitis, liver, lung and renal effects can occur.